Highest-materiality recent filing
Journey Medical Q1 revenue $16M (+21% YoY); Emrosi sales triple to $6.3M
Total revenue $16.0M, +21% YoY vs $13.1M; Emrosi revenue $6.3M vs $2.1M in Q1 2025.
Secured contract with third major GPO, expanding Emrosi commercial access from ~100M to >150M lives as of April 1, 2026.
Journey Medical FY2025 revenue $61.9M (+10% YoY); net loss narrows to $11.4M
Emrosi launch contributed $14.7M net revenue; ~53,000 prescriptions filled in FY2025.
Journey Medical Q3 2025 revenue $17.6M (+21% YoY); Emrosi sales $4.9M, prescriptions up 146%
Q3 2025 net revenues $17.6M, up 21% YoY from $14.6M; driven by Emrosi launch.
Maturity of $25M Term Loan extended from Dec 27, 2027 to June 27, 2028.
New Sales Agreement with B. Riley and Lake Street allows sale of up to 3,750,000 shares of common stock at the market.
Journey Medical Q2 revenue $15.0M; Emrosi sales $2.8M in first full quarter
Net loss of $3.8M ($0.16 EPS) vs $3.4M loss ($0.17 EPS) in Q2 2024.
Journey Medical expands Emrosi payer coverage to 65% of commercial lives from 29% in May 2025
Emrosi now has pharmacy benefit coverage for 65% of 187 million U.S. commercial lives, up from 29% in May 2025.
Journey Medical stockholders approve officer exculpation charter amendment
Amended certificate of incorporation effective June 24, 2025, adding officer exculpation.
Journey Medical to join Russell 2000 and Russell 3000 indexes effective June 27
Joins Russell 2000 and Russell 3000 indexes after market close on June 27, 2025.
Journey Medical reports Q1 net loss narrows to $4.1M; Emrosi launch underway
Net loss $4.1M ($0.18/sh) vs $10.4M loss ($0.53/sh) in Q1 2024.
Journey Medical appoints Ramsey Alloush as COO; remains General Counsel
Ramsey Alloush, previously General Counsel, appointed COO effective April 1, 2025.
Journey Medical reports FY2024 revenue $56.1M, net loss $14.7M; Emrosi launch underway
Total revenue $56.1M, down 29% YoY; product revenue net $55.1M (-8%) due to higher rebates and lower legacy volumes.
Journey Medical launches Emrosi for rosacea; first prescriptions filled
Emrosi (40 mg minocycline HCl modified-release) launched for inflammatory lesions of rosacea in adults.
Journey Medical expects $20.3M cash; reaffirms FY2024 revenue guidance $55-60M
Cash and cash equivalents expected to be $20.3 million as of December 31, 2024.
Journey Medical Q3 2024 revenue $14.6M, net loss $2.4M; Emrosi FDA approved for rosacea
FDA approved Emrosi (minocycline HCl ER 40 mg) for rosacea in adults; launch expected late Q1/early Q2 2025.
FDA approves Emrosi for rosacea; Q3 prelim revenue $14.6M, net loss $2.4M; FY guidance unchanged
FDA approved Emrosi (minocycline HCl ER 40 mg) for inflammatory lesions of rosacea in adults; initial supply expected late Q1 or early Q2 2025.
Journey Medical Q2 net product revenue $14.9M, net loss narrows to $3.4M; DFD-29 PDUFA Nov 4
Total net product revenue $14.9M, down 12% YoY but up 14% sequentially from Q1 2024.
Journey Medical increases credit facility to $25M, appoints new director Michael C. Pearce
Credit facility increased from $20M to $25M; additional $5M available upon FDA approval of DFD-29 by June 30, 2025.
Journey Medical shareholders approve 3M share increase and 10-year extension of 2015 stock plan
Stockholders approved an amendment to the 2015 Stock Incentive Plan adding 3,000,000 shares, for a total of 10,642,857 shares authorized.
Journey Medical Q1 rev $13M (+7% YoY); DFD-29 PDUFA Nov 4, 2024
Net loss of $10.4M ($0.53 loss per share) vs $10.1M loss ($0.57 loss per share) in Q1 2023.
Journey Medical appoints Joseph Benesch as permanent CFO effective April 26
Mr. Benesch had served as interim CFO since January 2023 and as Corporate Controller since November 2021.
Journey Medical reports FY2023 revenue $79.2M (+7% YoY); net loss narrows to $3.9M from $29.6M
Total revenues $79.2M vs $73.7M in 2022; growth driven by $19.0M Maruho licensing revenue.
On April 1, 2025, Ramsey Alloush, the General Counsel of Journey Medical Corporation (the “ Company ”), was appointed as the Company’s Chief Operating Officer.
appointed Michael C. Pearce, age 62, to serve on the Board
On April 26, 2024, the Board of Directors (the “ Board ”) of Journey Medical Corporation (the “ Company ”) appointed Joseph Benesch, age 57, as the Company’s permanent Chief Financial Officer.
Max materiality 0.85 · Median 0.60 · Most common event earnings